<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='112'><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1006865">Nascime Ltd</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA2888121">WO-2004012722</Patent><Status id="PUB">First Publication</Status><StatusDate>2004-02-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="22124">XTL Biopharmaceuticals Ltd</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="22124">XTL Biopharmaceuticals Ltd</ParentCompany><Patent id="PA2888121">WO-2004012722</Patent><Status id="PUB">First Publication</Status><StatusDate>2004-02-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1006865">Nascime Ltd</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA2888121">WO-2004012722</Patent><Status id="PRI">First Priority</Status><StatusDate>2002-07-31 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="22124">XTL Biopharmaceuticals Ltd</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Product</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="22124">XTL Biopharmaceuticals Ltd</ParentCompany><Patent id="PA2888121">WO-2004012722</Patent><Status id="PRI">First Priority</Status><StatusDate>2002-07-31 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Product (derivative)</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA2897870">WO-2004043920</Patent><Status id="PUB">First Publication</Status><StatusDate>2004-05-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Product (derivative)</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA2897870">WO-2004043920</Patent><Status id="PUB">First Publication</Status><StatusDate>2004-05-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Product (derivative)</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA2897870">WO-2004043920</Patent><Status id="PRI">First Priority</Status><StatusDate>2002-11-08 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Product (derivative)</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA2897870">WO-2004043920</Patent><Status id="PRI">First Priority</Status><StatusDate>2002-11-08 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1241">Prostate hyperplasia</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="140">Growth disorder</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="366">Genitourinary disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="486">Bladder disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1241">Prostate hyperplasia</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="140">Growth disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="366">Genitourinary disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="486">Bladder disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1241">Prostate hyperplasia</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="140">Growth disorder</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="366">Genitourinary disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="486">Bladder disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PUB">First Publication</Status><StatusDate>2005-12-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1241">Prostate hyperplasia</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="140">Growth disorder</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="366">Genitourinary disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="281">NMDA receptor antagonist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="486">Bladder disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1241">Prostate hyperplasia</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="140">Growth disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="366">Genitourinary disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="486">Bladder disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1241">Prostate hyperplasia</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="140">Growth disorder</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="366">Genitourinary disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="7293">Synergist</Action><AuthorityGroup/><Company id="30151">Dynogen Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="486">Bladder disease</Indication><LatestChange/><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Patent id="PA3068301">WO-2005117872</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="148">Headache</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3195229">WO-2006050520</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-05-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="443">Hyperthermia</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3195229">WO-2006050520</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-05-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="1023">Temperature disorder</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3195229">WO-2006050520</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-05-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="148">Headache</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3195229">WO-2006050520</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-11-05 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="443">Hyperthermia</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3195229">WO-2006050520</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-11-05 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="1023">Temperature disorder</TherapyArea></Row><Row><Action id="2946">Analgesic</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3195229">WO-2006050520</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-11-05 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-09-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Formulation</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="483">Urinary dysfunction</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3235458">WO-2006102029</Patent><Status id="PRI">First Priority</Status><StatusDate>2005-03-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1295">Neuropathic pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3460606">WO-2007014264</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-02-01 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1295">Neuropathic pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3460606">WO-2007014264</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-02-01 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1295">Neuropathic pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3460606">WO-2007014264</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>New use</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1295">Neuropathic pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3460606">WO-2007014264</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-24 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="106">Eating disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="238">Obesity</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="25">Anxiety disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="106">Eating disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="238">Obesity</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="25">Anxiety disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="106">Eating disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="238">Obesity</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="25">Anxiety disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-11-08 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="106">Eating disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="238">Obesity</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="25">Anxiety disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="151">Dopamine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="106">Eating disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="238">Obesity</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="25">Anxiety disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="106">Eating disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="187">Urinary incontinence</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="238">Obesity</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="684">Nutritional disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="25">Anxiety disorder</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="18077">Merck &amp; Co Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="93">Depression</Indication><LatestChange/><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Patent id="PA3566056">WO-2007127421</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-04-28 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="207">Psychiatric disorder</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="245">Osteoarthritis</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="2955">Non-steroidal anti-inflammatory</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="2955">Non-steroidal anti-inflammatory</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2955">Non-steroidal anti-inflammatory</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="245">Osteoarthritis</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="245">Osteoarthritis</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PUB">First Publication</Status><StatusDate>2008-01-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="285">Norepinephrine uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="245">Osteoarthritis</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="2955">Non-steroidal anti-inflammatory</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="2955">Non-steroidal anti-inflammatory</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="2955">Non-steroidal anti-inflammatory</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="245">Osteoarthritis</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="188">Inflammatory disease</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="20">Pain</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="3">5-HT uptake inhibitor</Action><AuthorityGroup/><Company id="1052448">Euthymics Bioscience Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><DrugRelationship>Component of Combination</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="245">Osteoarthritis</Indication><LatestChange/><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Patent id="PA3592729">WO-2008008474</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-07-11 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row></Rowset>